Evidence map›Paper›PMID 33526010›Full record

ArticleBMC infectious diseases2021

The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report.

Magnus Holter Bjørkto, Andreas Barratt-Due, Ingvild Nordøy, Christina Dörje, Eivind Galteland, Andreas Lind, Abdulkarim Hilli, Pål Aukrust, Geir Mjøen

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Magnus Holter BjørktoDepartment of Transplant Medicine, Oslo University Hospital, Birch-Reichenwaldsgate 34, NO-0483, Oslo, Norway. mbjorkto@gmail.com.ORCID http://orcid.org/0000-0002-2749-6558
Andreas Barratt-DueDivision of Critical care and Emergencies, Oslo University Hospital, Oslo, Norway.
Ingvild NordøySection for Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo, Norway.
Christina DörjeDepartment of Transplant Medicine, Oslo University Hospital, Birch-Reichenwaldsgate 34, NO-0483, Oslo, Norway.
Eivind GaltelandDepartment of Haematology, Oslo University Hospital, Oslo, Norway.
Andreas LindDepartment of Microbiology, Oslo University Hospital, Oslo, Norway.
Abdulkarim HilliDepartment of Internal Medicine, Diakonhjemmet Hospital, Oslo, Norway.
Pål AukrustSection for Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo, Norway.
Geir MjøenDepartment of Transplant Medicine, Oslo University Hospital, Birch-Reichenwaldsgate 34, NO-0483, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of complement inhibition is well established for complement mediated thrombotic microangiopathy, but its role in secondary forms of thrombotic microangiopathy is debated. We here present a case of thrombotic microangiopathy triggered by Capnocytophaga canimorsus, illustrating the diagnostic difficulties in discriminating between different thrombotic microangiopathies, and the dilemmas regarding how to treat this disease entity. CASE PRESENTATION: A previously healthy 56-year-old woman presented with fever and confusion. She was diagnosed with sepsis from Capnocytophaga canimorsus and thrombotic microangiopathy. Marked activation of both T-cells, endothelium and complement were documented. She was successfully treated with antimicrobial therapy, the complement inhibitor eculizumab and splenectomy. After several weeks, a heterozygote variant in complement factor B was localized, potentially implying the diagnosis of a complement mediated TMA over an isolated infection related TMA.

conclusionsWe discuss the possible interactions between complement activation and other findings in severe infection and argue that complement inhibition proved beneficial to this patient's rapid recovery.

Indexed as

Complement ActivationAntibodies, Monoclonal, HumanizedCapnocytophagaComplement Inactivating AgentsFemaleGram-Negative Bacterial InfectionsHumansMiddle AgedNorwaySepsisThrombotic MicroangiopathiesAntibodies, Monoclonal, HumanizedComplement Inactivating AgentseculizumabCapnocytophaga canimorsusCase reportComplementEculizumabThrombotic microangiopathy

Identifiers

PMID33526010
PMCPMC7852365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.